Correlation between free and total vancomycin serum concentrations in patients treated for Gram-positive infections

International Journal of Antimicrobial Agents

Volumn 34, Issue 6, 2009, Pages 555-560

  Berthoin, Karine ^a   Ampe, Els ^a,b   Tulkens, Paul M ^a   Carryn, Stephane ^a,c  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^c Eumedica Pharmaceuticals   (Belgium)

Author keywords

Free fraction; Protein binding; Reversed phase HPLC; Serum; Therapeutic drug monitoring; Vancomycin

Indexed keywords

CEFUROXIME; UNCLASSIFIED DRUG; VANCOMYCIN; ZINACEL;

ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; GRAM POSITIVE INFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PH; PREDICTION; PRIORITY JOURNAL; REFERENCE VALUE; SOLID PHASE EXTRACTION; ULTRAFILTRATION; VALIDATION PROCESS;

ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFUSIONS, INTRAVENOUS; SERUM; VANCOMYCIN;

EID: 70350619885     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.08.005     Document Type: Article

References (34)

1. Finch R.G., and Eliopoulos G.M. Safety and efficacy of glycopeptide antibiotics. J Antimicrob Chemother 55 Suppl. 2 (2005) ii5-ii13
2. Moellering Jr. R.C. Vancomycin: a 50-year reassessment. Clin Infect Dis 42 Suppl. 1 (2006) S3-S4
3. Corey G.R. Staphylococcus aureus bloodstream infections: definitions and treatment. Clin Infect Dis 48 Suppl. 4 (2009) S254-S259
4. Steinkraus G., White R., and Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 60 (2007) 788-794
5. Gould I.M. Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus. Int J Antimicrob Agents 31 Suppl. 2 (2008) 1-9
6. Stevens D.L. The role of vancomycin in the treatment paradigm. Clin Infect Dis 42 Suppl. 1 (2006) S51-S57
7. Rybak M., Lomaestro B., Rotschafer J.C., Moellering Jr. R., Craig W., Billeter M., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66 (2009) 82-98
8. Gudiol F., Aguado J.M., Pascual A., Pujol M., Almirante B., Miro J.M., et al. Consensus document for the treatment of bacteremia and endocarditis caused by methicillin-resistant Staphylococcus aureus. Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica [in Spanish]. Enferm Infecc Microbiol Clin 27 (2009) 105-115
9. Mouton J.W., Theuretzbacher U., Craig W.A., Tulkens P.M., Derendorf H., and Cars O. Tissue concentrations: do we ever learn?. J Antimicrob Chemother 61 (2008) 235-237
10. Lamer C., de Beco V., Soler P., Calvat S., Fagon J.Y., Dombret M.C., et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 37 (1993) 281-286
11. Rybak M.J. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 42 Suppl. 1 (2006) S35-S39
12. Stratton C.W., and Weeks L.S. Effect of human serum on the bactericidal activity of daptomycin and vancomycin against staphylococcal and enterococcal isolates as determined by time-kill kinetic studies. Diagn Microbiol Infect Dis 13 (1990) 245-252
13. Bailey E.M., Rybak M.J., and Kaatz G.W. Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Antimicrob Agents Chemother 35 (1991) 1089-1092
14. Ackerman B.H., Taylor E.H., Olsen K.M., Abdel-Malak W., and Pappas A.A. Vancomycin serum protein binding determination by ultrafiltration. Drug Intell Clin Pharm 22 (1988) 300-303
15. Lindholm D.D., and Murray J.S. Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis. N Engl J Med 274 (1966) 1047-1051
16. Wittendorf R.W., Swagzdis J.E., Gifford R., and Mico B.A. Protein binding of glycopeptide antibiotics with diverse physical-chemical properties in mouse, rat, and human serum. J Pharmacokinet Biopharm 15 (1987) 5-13
17. Krogstad D.J., Moellering Jr. R.C., and Greenblatt D.J. Single-dose kinetics of intravenous vancomycin. J Clin Pharmacol 20 (1980) 197-201
18. Albrecht L.M., Rybak M.J., Warbasse L.H., and Edwards D.J. Vancomycin protein binding in patients with infections caused by Staphylococcus aureus. DICP 25 (1991) 713-715
19. Helgason K.O., Thomson A.H., and Ferguson C. A review of vancomycin therapeutic drug monitoring recommendations in Scotland. J Antimicrob Chemother 61 (2008) 1398-1399
20. Moise P.A., Forrest A., Bhavnani S.M., Birmingham M.C., and Schentag J.J. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm 57 Suppl. 2 (2000) S4-9
21. Pea F., Porreca L., Baraldo M., and Furlanut M. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother 45 (2000) 329-335
22. Fernández de Gatta Mdel M., Santos Buelga D., Sánchez Navarro A., Dominguez-Gil A., and García M.J. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis. Clin Pharmacokinet 48 (2009) 273-280
23. Ampe E., Berthoin K., Delaere B., Noirhomme S., Tulkens P.M., Hecq J., et al. Assay of free and total vancomycin serum concentrations with E-test-based determination of MICs in patients treated by continuous infusion for severe staphylococcal and enterococcal infections. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/46th Annual Meeting of the Infectious Diseases Society of America (IDSA). 25-28 October 2008, Washington, DC (2008), ASM Press, Washington, DC
24. Zhang T., Watson D.G., Azike C., Tettey J.N., Stearns A.T., Binning A.R., et al. Determination of vancomycin in serum by liquid chromatography-high resolution full scan mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 857 (2007) 352-356
25. Denooz R., and Charlier C. Simultaneous determination of five β-lactam antibiotics (cefepim, ceftazidim, cefuroxim, meropenem and piperacillin) in human plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 864 (2008) 161-167
26. Li L., Miles M.V., Lakkis H., and Zaritsky A.L. Vancomycin-binding characteristics in patients with serious infections. Pharmacotherapy 16 (1996) 1024-1029
27. Chen Y., Norris R.L., Schneider J.J., and Ravenscroft P.J. The influence of vancomycin concentration and the pH of plasma on vancomycin protein binding. J Pharmacol Toxicol Methods 28 (1992) 57-60
28. Sun H., Maderazo E.G., and Krusell A.R. Serum protein-binding characteristics of vancomycin. Antimicrob Agents Chemother 37 (1993) 1132-1136
29. Cantu T.G., Dick J.D., Elliott D.E., Humphrey R.L., and Kornhauser D.M. Protein binding of vancomycin in a patient with immunoglobulin A myeloma. Antimicrob Agents Chemother 34 (1990) 1459-1461
30. Moise-Broder P.A., Forrest A., Birmingham M.C., and Schentag J.J. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 43 (2004) 925-942
31. Craig W.A. Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 17 (2003) 479-501
32. Ingram P.R., Lye D.C., Tambyah P.A., Goh W.P., Tam V.H., and Fisher D.A. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother 62 (2008) 168-171
33. Fanos V., and Cataldi L. Renal transport of antibiotics and nephrotoxicity: a review. J Chemother 13 (2001) 461-472
34. Cantu T.G., Yamanaka-Yuen N.A., and Lietman P.S. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 18 (1994) 533-543